Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Trinity Research Group

Neither a doctor nor a teaching hospital

Research payments

$1,678,101

156 payments

Through program year 2025, Trinity Research Group is reported as receiving $1,678,101 in research payments, across 156 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $684,051 32
2024 Research $424,636 34
2023 Research $309,666 44
2022 Research $145,208 34
2021 Research $14,204 1
2020 Research $70,362 6
2019 Research $29,975 5

Breakdown

Who paid Research payments · program years 2019–2025
  1. Glaukos Corporation $1,438,986 111 payments
  2. Sight Sciences, Inc. $119,190 12 payments
  3. AbbVie, Inc. $94,382 28 payments
  4. Kala Pharmaceuticals, Inc. $17,100 4 payments
  5. Merit Medical Systems Inc $8,444 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. Multicenter, Randomized, Double-masked, Parallel Group Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intracameral implant) in Conjunction with Cataract Surgery vs. Cataract Surgery Alone $382,663 7 payments
  2. Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension $258,359 19 payments
  3. A Prospective, Multicenter Study of the Glaukos Istent Infinite Trabecular Micro-Bypass System Model Is3 in Subjects With Mild to Moderate Primary Open-Angle Glaucoma $185,602 8 payments
  4. A Phase 3, Multi-center, Randomized, Double-masked, Placebo/Sham-controlled Study to Evaluate the Safety and Efficacy of Oxygen Enriched, Non-invasive Epithelium-on Corneal Collagen Cross-linking in Eyes with Keratoconus $162,509 10 payments
  5. A Phase 3, Multi-center, Randomized, Double-masked, Placebo/Sham-controlled Study to Evaluate the Safety and Efficacy of Oxygen Enriched, Non-invasive Epithelium-on Corneal Collagen Cross-linking in Eyes with Keratoconus $155,513 14 payments
  6. A Dose Ranging, Multicenter, Sham-Controlled Study to Evaluate the Safety and Efficacy of Corneal Cross-linking in Subjects with Keratoconus $104,222 13 payments
  7. A Dose Ranging, Multicenter, Sham-Controlled Study to Evaluate the Safety and Efficacy of Corneal Cross-linking in Subjects with Keratoconus $73,615 9 payments
  8. Prospective Multicenter Post Market Study of Use of the OMNI Surgical System in Combination with Cataract Extraction in Open Angle Glaucoma $68,642 4 payments
  9. Long-term Safety and Efficacy Extension Trial of Bimatoprost SR $64,367 16 payments
  10. Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, USP, 0.5% $30,485 11 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record